C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by C4 Therapeutics, Inc. on June 22, 2022. The report details the voting results for director elections, executive compensation, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
- Director Elections: Stockholders elected Bruce Downey and Glenn Dubin as Class II directors to serve until the 2025 annual meeting.
- Bruce Downey: 16,221,318 votes for; 13,812,875 votes withheld.
- Glenn Dubin: 18,740,397 votes for; 11,293,796 votes withheld.
- Compensation Frequency: Stockholders voted on the frequency of future advisory votes on executive compensation. The "One Year" option received the most support with 29,265,694 votes.
- Executive Compensation: The non-binding advisory vote to approve named executive officer compensation passed with 29,207,646 votes for and 262,241 votes against.
- Auditor Ratification: Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 41,468,547 votes for and 25,815 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of shareholder voting results.
Key Facts for Investor Verification
- Confirmation of the tenure for newly elected directors Bruce Downey and Glenn Dubin (until 2025).
- Verification of the approved frequency for future executive compensation advisory votes (One Year).
- Confirmation that KPMG LLP remains the independent auditor for the 2022 fiscal year.
- Review of the significant number of broker non-votes (11,471,383) across multiple proposals.